1038358-13-2

Upstream product

• 39201-89-3 (E)-3,4,5-trimethoxybenzaldehyde oxime 
• 79-10-7 acrylic acid 

Downstream Products

• 1394002-11-9 N-(4-chloro-2-(cyclohexylcarbamoyl)-6-methylphenyl)-3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide 
• 1394002-14-2 N-(4-chloro-2-(diethylcarbamoyl)-6-methylphenyl)-3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide 
• 1394002-17-5 N-(4-chloro-2-methyl-6-(methylcarbamoyl)phenyl)-3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide 
• 1394002-05-1 N-(4-chloro-2-methyl-6-(propylcarbamoyl)phenyl)-3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide 
• 1394002-08-4 N-(4-chloro-2-(isopropylcarbamoyl)-6-methylphenyl)-3-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide 

Relevant academic research and scientific papers

Anthranilic acid-based diamides derivatives incorporating aryl-isoxazoline pharmacophore as potential anticancer agents: Design, synthesis and biological evaluation

A series of novel anthranilic diamides derivatives containing aryl-isoxazoline moiety were designed and synthesized as a part of our ongoing search for potential anticancer agents. Their structures were confirmed by 1H NMR, 13C NMR and ESI-MS analyses. The preliminary assays showed that some of the compounds displayed moderate to good antitumor activities against human lung cancer (NCI-H460), hepatocellular liver carcinoma (HepG2), gastric cancer (SGC-7901 and BGC-823) and breast epithelial adenocarcinoma (MCF-7) cell lines at μM level, which might be developed as novel lead scaffold for potential anticancer agents.